PL3351539T3 - Krystaliczny kompleks monohydratowy 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(beta-d-glukopiranoz-1-ylo)-benzenu i proliny w wodzie krystalicznej (1:1:1), sposoby jego wytwarzania i jego zastosowanie jako inhibitor sglt - Google Patents
Krystaliczny kompleks monohydratowy 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(beta-d-glukopiranoz-1-ylo)-benzenu i proliny w wodzie krystalicznej (1:1:1), sposoby jego wytwarzania i jego zastosowanie jako inhibitor sgltInfo
- Publication number
- PL3351539T3 PL3351539T3 PL18155079.9T PL18155079T PL3351539T3 PL 3351539 T3 PL3351539 T3 PL 3351539T3 PL 18155079 T PL18155079 T PL 18155079T PL 3351539 T3 PL3351539 T3 PL 3351539T3
- Authority
- PL
- Poland
- Prior art keywords
- glucopyranos
- proline
- cyclopropyl
- cyano
- beta
- Prior art date
Links
- PESZPPAQWQMZAM-XNBWIAOKSA-N 2-[(4-cyclopropylphenyl)methyl]-4-[(2r,3r,4s,5s,6r)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(C#N)C(CC=2C=CC(=CC=2)C2CC2)=C1 PESZPPAQWQMZAM-XNBWIAOKSA-N 0.000 title 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3351539T3 true PL3351539T3 (pl) | 2023-03-06 |
Family
ID=48874313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18155079.9T PL3351539T3 (pl) | 2012-07-26 | 2013-07-25 | Krystaliczny kompleks monohydratowy 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(beta-d-glukopiranoz-1-ylo)-benzenu i proliny w wodzie krystalicznej (1:1:1), sposoby jego wytwarzania i jego zastosowanie jako inhibitor sglt |
| PL13740309T PL2877460T3 (pl) | 2012-07-26 | 2013-07-25 | Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13740309T PL2877460T3 (pl) | 2012-07-26 | 2013-07-25 | Krystaliczny kompleks 1-cyjano-2-(4-cyklopropylo-benzylo)-4-(ß-D-glukopiranoz-1-ylo)-benzenu, sposoby jego wytwarzania i jego zastosowanie do wytwarzania leków |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9145434B2 (enExample) |
| EP (3) | EP4166548A1 (enExample) |
| JP (2) | JP6538556B2 (enExample) |
| CN (2) | CN108774200A (enExample) |
| AR (1) | AR091908A1 (enExample) |
| AU (1) | AU2013294947B2 (enExample) |
| BR (1) | BR112015001327B1 (enExample) |
| CA (1) | CA2878698C (enExample) |
| DK (2) | DK3351539T3 (enExample) |
| EA (2) | EA025438B1 (enExample) |
| ES (2) | ES2937665T3 (enExample) |
| FI (1) | FI3351539T3 (enExample) |
| HR (2) | HRP20230081T1 (enExample) |
| HU (1) | HUE061450T2 (enExample) |
| LT (1) | LT3351539T (enExample) |
| MX (1) | MX357906B (enExample) |
| PL (2) | PL3351539T3 (enExample) |
| PT (2) | PT3351539T (enExample) |
| RS (1) | RS63881B1 (enExample) |
| SG (1) | SG11201500574QA (enExample) |
| SI (2) | SI2877460T1 (enExample) |
| TW (1) | TW201418275A (enExample) |
| WO (1) | WO2014016381A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP2981269B9 (en) | 2013-04-04 | 2023-12-06 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
| PL3082829T3 (pl) * | 2013-12-17 | 2021-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Inhibitory sglt2 do leczenia zaburzeń metabolicznych u zwierząt kotowatych |
| PL3096765T3 (pl) | 2014-01-23 | 2019-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt psowatych |
| KR102662473B1 (ko) | 2014-04-01 | 2024-05-03 | 베링거잉겔하임베트메디카게엠베하 | 말과 동물에서 대사 장애의 치료 |
| CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
| AU2015320975B2 (en) | 2014-09-25 | 2020-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| KR20170060035A (ko) * | 2014-09-30 | 2017-05-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정 |
| CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
| NZ739429A (en) | 2015-08-27 | 2023-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| KR102226465B1 (ko) * | 2016-05-28 | 2021-03-11 | 하이난 수안주 파마 코포레이션 리미티드 | 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형 |
| EP3668846A1 (en) * | 2017-12-19 | 2020-06-24 | Boehringer Ingelheim Vetmedica GmbH | Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water |
| US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
| CN118615450A (zh) | 2020-02-17 | 2024-09-10 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途 |
| WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
| CA3224673A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| AU2023277704A1 (en) | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| AU2024233233A1 (en) | 2023-03-06 | 2025-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| CN121039113A (zh) | 2023-04-24 | 2025-11-28 | 勃林格殷格翰动物保健有限公司 | 维格列净与所选共晶形成剂的结晶复合物、其制备方法及其在制备药物中的用途 |
| WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| TW202508455A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002083066A2 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1581543A4 (en) * | 2003-01-03 | 2008-03-19 | Bristol Myers Squibb Co | METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS |
| CN103435581B (zh) * | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| DE602006018961D1 (de) * | 2005-09-08 | 2011-01-27 | Boehringer Ingelheim Pharma | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG |
| EA200801773A1 (ru) * | 2006-02-15 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| CN103319445B (zh) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| HRP20161648T1 (hr) * | 2008-08-22 | 2017-02-10 | Theracos Sub, Llc | Postupak za pripravu sglt2 inhibitora |
| ATE540040T1 (de) | 2008-08-28 | 2012-01-15 | Pfizer | Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate |
| WO2010048358A2 (en) | 2008-10-22 | 2010-04-29 | Auspex Pharmaceutical, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP2981269B9 (en) | 2013-04-04 | 2023-12-06 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
- 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
- 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
- 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
- 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
- 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
- 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
- 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
- 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
- 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
- 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061450T2 (hu) | 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása | |
| PL3110901T3 (pl) | Zastosowanie r-1233 w cieczowych urządzeniach chłodzących | |
| GB2491118B (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| IL228967B (en) | Heterocyclic compounds as kinase inhibitors | |
| EP2528455A4 (en) | METHODS OF TREATING GLYCOSIDE MIXTURES TO OBTAIN ONE OR MORE OF THESE GLYCOSIDES IN PURE FORM | |
| IL232822B (en) | Furinone hydrochloride derivative, its crystals, preparations containing it and its uses | |
| IL231227A0 (en) | Compounds and preparations as kit inhibitors - c | |
| IL231226A0 (en) | Compounds and preparations as kit inhibitors - c | |
| SI2697218T1 (sl) | Postopek za pripravo spojin, koristnih kot zaviralci sglt2 | |
| IL250337A0 (en) | Preparations for use in the treatment of nephropathy and methods for their preparation | |
| ZA201308541B (en) | Compounds for use in treatment of mucositis | |
| IL225352A0 (en) | Process for the preparation of cdk-pan inhibitors according to formula (i) and intermediates in the preparation | |
| GB2490246B (en) | Use of compositions for growth and vigour in soybean | |
| EP2927226A4 (en) | MONOHYDRATE CRYSTAL FROM FIMASARTANKALIUM SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACOLOGICAL COMPOSITION THEREWITH | |
| GB2490250B (en) | Use of compositions for growth and vigour in cotton | |
| GB201113009D0 (en) | Improvements in and relating to fluid sample holders | |
| IL212725A (en) | Glycerol Preparation for Non-surgical Conjunctivochalysis | |
| GB201105928D0 (en) | Improvements in or relating to cold storage | |
| GB201108916D0 (en) | Improvements in or relating to cold storage | |
| GB201105929D0 (en) | Improvements in or relating to cold storage | |
| GB201110660D0 (en) | Improvements in or relating to cold storage | |
| GB201105927D0 (en) | Improvements in or relating to cold storage | |
| GB201113134D0 (en) | Improvements in or relating to cold storage | |
| GB201105923D0 (en) | Improvements in or relating to cold storage | |
| GB201105489D0 (en) | Improvements in or relating to cold storage |